(PRWEB) September 26, 2012
XTN TALE effectors empower customers to edit, ko or knock-in any sequence for genome editing, with applications in cells, animals and plants. XTNTALEN nucleases resemble Zinc Finger nucleases, but bind to DNA on the single base level showing an extremely flexible and particular genome editing innovation. Transposagens XTN TAL nucleases and piggyBac technology can also be made use of in combination for Footprint-Free genetic adjustment.
. Transposagen’s certified FLASH XTN TALEN effector manufacturing system enhances efficiency and decreases timelines and expense. Site-specific genetic adjustment and gene modifying is now more budget-friendly than ever.
. The FLASH production system is the fastest and most economical approach to create gene editing tools, with all the exact same applications of other individual site-specific nucleases, such as zinc finger nucleases, stated Eric Ostertag, President and CEO of Transposagen.
. Validated: Transposagen’s XTN TALEN Nucleases are series verified and supplied in pre-tested expression vectors for optimal efficiency.
. Exact and Reliable: XTNTALEN Nucleases are assured to bind and cut the target website or we will make a new one free of charge.
. Affordable and Flexible: Custom-made XTN TALEN Nucleases are fairly priced and have definitely no restrictions on use.
. Speed: Fastest turnaround time in the market.
. GEN Post: Accessible TALENs
. About Transposagen Biopharmaceuticals Inc. . Transposagen Biopharmaceuticals, Inc., a Lexington, KY-based company, is an around the world leader in technologies and services for genetic adjustment. Transposagen is dedicated to showing better disease models through genetic adjustment. Transposagen concentrates on customized and off-the-shelf XTN site-specific nucleases, animal models, cell lines, stem cells and advanced study devices and innovations to enhance drug discovery and development research. These unique innovations and services for hereditary adjustment offer consumers the ability to produce almost any genetic adjustment in any genome for both study and protein manufacturing purposes.
. . More Biotechnology News Press Releases